Kimberly Powell, NVIDIA’s Vice President of Healthcare, told GEN that the new partnership with GSK and development of Cambridge-1 reflected a “natural evolution for Nvidia . . .
- Artificial Intelligence
- Information Management
- Bioinformatics
- Data Analysis
- Drug Discovery
- GEN Edge
- GlaxoSmithKline
- OMICs
- Sequencing
NVIDIA Powers Up in Drug Discovery
With GSK partnership and new supercomputer, GPU inventor ready for action in AI-based healthcare
NVIDIA’s new Cambridge-1 supercomputer will be an NVIDIA DGX SuperPOD™ system designed to deliver more than 400 petaflops of AI performance and 8 petaflops of Linpack performance. Users of Cambridge-1 will include GlaxoSMithKline(GSK), AstraZeneca, and Oxford Nanopore Technologies. [NVIDIA]
